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ABSTRACT 
Objectives: Re-infection after treatment for Chlamydia trachomatis or Neisseria 
gonorrhoeae reduces the effect of control interventions. We explored the impact of 
delays in partner treatment on the expected probability of re-infection of index cases 
using a mathematical model. 
Methods: We used previously reported parameter distributions to calculate the 
probability that index cases would be re-infected by their untreated partners. We then 
assumed different delays between index case and partner treatment to calculate the 
probabilities of re-infection. 
Results: In the absence of partner treatment, the medians of the expected re-infection 
probabilities are 19.4% (interquartile range (IQR) 9.2–31.6%) for chlamydia and 
12.5% (IQR 5.6–22.2%) for gonorrhoea. If all current partners receive treatment three 
days after the index case, the expected re-infection probabilities are 4.2% (IQR 2.1–
6.9%) for chlamydia and 5.5% (IQR 2.6–9.5%) for gonorrhoea. 
Conclusions: Quicker partner referral and treatment can substantially reduce re-
infection rates for chlamydia and gonorrhoea. The formula we used to calculate re-
infection rates can be used to inform the design of randomised controlled trials of 
novel partner notification technologies like accelerated partner therapy.  
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KEY MESSAGES BOX 
• Our formula calculates the probability of re-infection of index cases with 
chlamydia and gonorrhoea by their untreated partners. 
• Quicker treatment of partners can substantially reduce re-infection rates for 
chlamydia and gonorrhoea. 
• The intuitive and flexible formula can be easily adapted to inform the design of 
studies such as randomised controlled trials. 
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INTRODUCTION 
If sexual partners are not treated concurrently for Chlamydia trachomatis (chlamydia) 
or Neisseria gonorrhoeae (gonorrhoea), the index case may be re-infected.1 2 Our 
previous work has shown that the impact of screening interventions for chlamydia 
infection is limited by re-infection from untreated partners.3 Repeated infection might 
also increase the risk of adverse sequelae, particularly in women. 
 
Partner notification (PN) limits re-infection in people who have been treated for 
chlamydia or gonorrhoea. Expedited partner therapy and accelerated partner therapy 
are PN technologies that reduce the time between diagnosis and treatment of the index 
patient to partner referral and treatment.1 4 In randomised controlled trials (RCT), 
expedited partner therapy reduced the incidence of repeated detection of either 
chlamydia or gonorrhoea infection.1 It was not possible to determine the proportion of 
repeated infections that resulted from re-infection by an untreated partner, infection 
from a new partner, or antibiotic treatment failure. The incremental benefits of 
reducing the delay to partner treatment on re-infection of index cases by partners who 
have not yet been treated are not well understood. 
 
The effects of PN can be explored with mathematical models. Dynamic transmission 
models often assume that index cases and their partners are treated at the same time so 
the risk of re-infection with different delays to partner treatment cannot be studied.3 
Calculating the probability of re-infection requires a model that takes into account 
competing risks of re-infection, partner treatment, clearance of infection in the partner, 
and dissolution of the sexual partnership. Such a model could help us better 
5 
understand the differences between chlamydia and gonorrhoea re-infection after 
treatment. 
 
The objective of this study was to develop a model to calculate the expected 
probability with which treated index cases will be re-infected with chlamydia and 
gonorrhoea by their untreated partners. We explore the effect that varying the time 
delay to partner treatment has on re-infection of index cases. 
METHODS 
Probability of re-infection 
We devised a formula to calculate the probability of re-infection of index cases by 
their as yet untreated partners: 
𝑃 = 𝑝!×𝑝! 𝑓×𝛽𝑓×𝛽 + 𝛾 + 𝜎 + 𝛿 + (1− 𝜀)× 𝛿𝑓×𝛽 + 𝛾 + 𝜎 + 𝛿× 𝑓×𝛽𝑓×𝛽 + 𝛾 + 𝜎  
pp is the probability that the index case is in an ongoing sexual partnership and pi is the 
probability that the partner is infected. The first term in the brackets represents the 
probability that the index case is re-infected before the partner is treated, the partner’s 
infection is cleared, or the sexual partnership is dissolved. The successfully treated 
index case is assumed to engage in new sex acts with the partner at a frequency f, 
where the infection can transmit at a per sex act transmission probability β. 
Transmission can occur until the partner is either treated at rate δ (1/δ is the average 
delay in the time to partner treatment), the infection is spontaneously cleared in the 
partner at rate γ, or the sexual partnership dissolves at rate σ. The second term in the 
brackets corresponds to the probability that re-infection occurs in cases in which the 
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partner has not been successfully treated, where ε is the treatment efficacy in the 
partner. We assume that all probabilities and events are independent of each other. 
Parameter values 
To calculate the expected range of re-infection probabilities, we generated 106 
parameter sets by randomly drawing from uniform (U(a, b) from a to b) or binomial 
(B(n, p) with sample size n and probability p) distributions. Unless otherwise noted, 
the parameter ranges are based on the studies by Althaus et al.5 and Garnett et al.6 and 
the papers they cite. The probability that index cases are in an on-going partnership 
was assumed to be in the interval U(0, 1). Chlamydia or gonorrhoea positivity in 
current partners is drawn from B(77, 0.69) and B(188, 0.80).7 We assumed an average 
duration of sexual partnerships in chlamydia-infected individuals from U(1 week, 6 
months). For gonorrhoea-infected individuals, we assumed that sexual partnerships are 
shorter (U(1 day, 2 weeks)). For both infections, the frequency of sex acts was drawn 
from U(1, 7) per week.8 The per sex act transmission probabilities for chlamydia and 
gonorrhoea were drawn from U(0.06, 0.167) and U(0.19, 0.53). The average duration 
of chlamydia and gonorrhoea infection in the current partner is drawn from U(6, 12) 
and U(1, 6) months. We assume that the PN rate is 100%, and that the treatment 
efficacy for a notified partner was 90% for chlamydia and 100% for gonorrhoea. 
RESULTS 
We compare re-infection with chlamydia and gonorrhoea in the absence of PN to 
expected re-infection in the presence of PN and used the following average delays to 
treatment of the current partner: 14 days, 3 days, and 1 day (figure 1). Without PN, 
median re-infection probabilities from the 106 parameter combinations are 19.4% 
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(interquartile range (IQR) 9.2-31.6%) for chlamydia and and 12.5% (IQR 5.6–22.2%) 
for gonorrhoea. The values for chlamydia re-infection support previous observations in 
empirical and mathematical modeling studies.2 9 Less is known about gonorrhoea re-
infection in the absence of PN. Although the per sex act transmission probability for 
gonorrhoea is higher than for chlamydia, we find a lower probability of re-infection 
because sexual partner change is more frequent and partnerships do not last as long in 
gonorrhoea-infected individuals. 
 
Reducing the delay between index case and partner treatment from 14 days10 to 1 or 3 
days4 substantially reduces the risk of re-infection. For chlamydia, median 
probabilities of re-infection are 8.8% (IQR 4.3–14.6%), 4.2% (IQR 2.1–6.9%) and 
2.8% (IQR 1.4-4.6%) for decreasing delays of partner treatment. For gonorrhoea, the 
respective probabilities are 9.7% (IQR 4.5–17.1%), 5.5% (IQR 2.6-9.5%) and 2.6% 
(IQR 1.3-4.6%). Thus, the probability of re-infection after treatment for chlamydia and 
gonorrhoea become more alike as the time to partner treatment grows shorter. 
DISCUSSION 
Our formula provides a general framework within which one can assess the risk that 
index cases treated for chlamydia or gonorrhoea will be re-infected by their, as yet, 
untreated partners. We found that reducing the time to partner treatment to 1 to 3 days 
can reduce re-infection of treated index cases from untreated partners substantially. 
The formula is intuitive and flexible, and can be easily adaptated to model variations 
in the mechanisms of transmission and PN. For example, it can easily accommodate 
reduced frequency of sexual intercourse or condom use.  
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Because we do not know all the parameters that influence transmission of chlamydia 
and gonorrhoea, the generalisability of our findings is limited. There are more studies 
with prospectively collected data about chlamydia re-infection than for gonorrhoea, at 
least for women.2 Re-infection rates might differ between women and men but we did 
not consider sex-specific parameters in this study. We had information about the 
average length of sexual partnerships of chlamydia-infected5 but not gonorrhoea-
infected individuals. We assumed that treated index cases can only be re-infected by a 
single current partner but acknowledge that concurrent sexual partnerships also exist. 
Finally, our study concentrates only on re-infection of index cases and does not 
investigate the effects that different periods of delay to partner treatment might have 
on transmission in the population. Without dynamic transmission models we could not 
address the latter question, but we have shown recently that preventing chlamydia re-
infection of the treated index is the most effective way of increasing the population-
level effect of PN.3 
 
The results from our formula can be compared with findings from empirical studies. 
For example, recurrent or persistent chlamydia and gonorrhoea infection were 
measured in an RCT of the effects of expedited partner therapy.1 Our calculated risk 
of re-infection for a PN delay of 14 days are consistent with the RCT findings for 
standard referral of partners. Golden et al.1 further found that expedited partner 
therapy reduced persistent or recurrent infections more for gonorrhoea than for 
chlamydia. Our study did not replicate this finding but this might be because one could 
not distinguish between treatment failure in index cases and repeated infection from 
current or new partners in the RCT. 
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Our model can help to understand the potential impact on chlamydia and gonorrhoea 
re-infection of reducing delays to partner treatment. Its value will increase as we 
improve our estimates of transmission and sexual behaviour, particularly for 
individuals infected with gonorrhoea. We conclude that PN technologies that shorten 
delays to partner treatment, such as expedited and accelerated partner therapy, 
substantially reduce index case re-infection by untreated partners, when compared 
with standard patient referral. 
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Figure legends 
 
Figure 1 Probabilities of re-infection of treated index cases by their untreated 
partners. Different delays to partner treatment are contrasted to the scenario without 
any partner notification (no PN). The figures show box-plots of 106 different 
parameter combinations sampled from the distributions given in Methods. The whisker 
of the first two box plots extend to 65.2% for chlamydia and 47.1% for gonorrhoea. 
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